secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-01-31T23:59:59+00:00
Accession:  0000885725-24-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BSX Q4 sales $3.73B (+14.9% reported), adj EPS $0.55; FY2024 adj EPS guidance $2.23-$2.27
--------------------------------------------------------------------------------

- Q4 net sales $3.725B (+14.9% reported); GAAP EPS $0.34, adj EPS $0.55 beat guidance ranges.
- FY2023 net sales $14.240B (+12.3% reported); GAAP EPS $1.07; adj EPS $2.05 versus $1.71 prior year.
- FY2024 guidance: reported sales growth 8.5-9.5%; GAAP EPS $1.38-$1.42; adj EPS $2.23-$2.27.
- FDA approved FARAPULSE PFA System for paroxysmal atrial fibrillation; enrollment in AVANT GUARD trial commenced.
- Agreed to acquire Axonics (AXNX) for urinary/bowel dysfunction treatment; Relievant Medsystems acquisition completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/0000885725-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/bsx-20240131.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer